Mizuho Medy

Mizuho Medy Co., Ltd. is a Japanese company in the in-vitro diagnostics field. It was established in November 1977 in Hakata-ku, Fukuoka as a clinical reagent sales company, relocated its head office to Tosu, Saga in 1981, and changed its name to Mizuho Medy in 1983. The company develops, manufactures, and sells in-vitro diagnostic products, including the fully automated genetic analyzer Smart Gene, the Helicobacter pylori nucleic acid kit Smart Gene H. pylori G, and the rapid infectious disease diagnostic system Quick Chaser. It has been listed on the Tokyo Stock Exchange since 2015 and moved to the Standard Market in 2022.

Mizuho Medy was established in November 1977 in Hakata-ku, Fukuoka as a clinical reagent sales company with capital of 5 million yen. In September 1981, it relocated its head office to Tosu, Saga and changed its business purpose to manufacturing and selling in-vitro diagnostic drugs. In March 1983, it changed its name to Mizuho Medy Co., Ltd. It opened a Tokyo sales office in August 1983 and an Osaka sales office in October 1983, and began overseas exports in May 1984. It opened a Nagoya sales office in July 1986. In December 1988, capital was increased to 95 million yen, and in September 1989 the head office was relocated with a new factory completed in Tosu, Saga. In December 1990, capital was increased to 329.75 million yen. In March 1995, the head office factory was expanded. In October 1997, an OTC division was established for pharmacies and drugstores. In October 2004, sales of products for practitioners began with influenza test reagents. In March 2005, the head office warehouse was expanded. In September 2008, ISO13485 certification was obtained. In September 2010, the head office factory was expanded, and in September 2012, the head office testing and research building was expanded. In December 2015, the company listed on the Tokyo Stock Exchange JASDAQ market and increased capital to 464.54 million yen. In February 2018, it obtained domestic manufacturing and marketing approval for a respiratory infectious disease genetic test reagent (Smart Gene Myco), and in October 2018 began sales of the fully automated genetic analyzer (Smart Gene) and the respiratory infectious disease genetic test reagent (Smart Gene Myco). In November 2018, it moved to the Second Section of the Tokyo Stock Exchange. In May 2019, the Kurume Factory and Genetic Research Institute were completed in Kurume, Fukuoka, and began operation in September 2019. In August 2020, it began selling a COVID-19 genetic test kit (Smart Gene SARS-CoV-2 detection reagent) as a research reagent covered by public medical insurance. In April 2021, it began selling Smart Gene SARS-CoV-2, which obtained approval as an in-vitro diagnostic drug. In April 2022, due to the Tokyo Stock Exchange market restructuring, it moved from the Second Section to the new Standard Market.

• Smart Gene

  Fully automated genetic analyzer

• Smart Gene H. pylori G

  Helicobacter pylori nucleic acid kit

• Quick Chaser

  Rapid infectious disease diagnostic system

• P-Check / LH Clearly

  Ovulation day prediction test

• Pregnancy test

  Pregnancy test

1. 1株式会社ミズホメディーmizuho-m.co.jp
2. 2会社沿革 | 株式会社ミズホメディーmizuho-m.co.jp
3. 3会社情報 | 株式会社ミズホメディーmizuho-m.co.jp
4. 4ご挨拶/当社運営の基本方針 | 株式会社ミズホメディーmizuho-m.co.jp
5. 5Mizuho Medywikidata.org